Author:
Kostenko Stanislav M.,Tulinova Irina A.,Zemskov Andrey M.,Dushkina Natalya V.,Mukha Tatiana A.,Kostenko Dmitry S.,Zotova Elena E.
Abstract
Delayed innate and adaptive immune response lay behind the pathogenesis of the novel coronavirus infection. COVID-19 is a multisystem disease affecting various human organs. More than a third of the patients have hepatic impairments. This can be caused by both direct cytopathic effect and immune-mediated mechanisms. In the Russian Federation, favipiravir, a DNA-Dependent RNA Polymerase inhibitor, is recommended for etiotropic therapy of the novel coronavirus infection. Research shows that the medication can reduce the viral load and the length of hospital stay. However, the affect of favipiravir on the immune response remains uncertain.
Reference18 articles.
1. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (covid-19). Министерство здравоохранения Российской Федерации. Версия 17 (14.12.2022)
2. Deidda S, Tora L, Firinu D, Del Giacco S, Campagna M, Meloni F, Orrù G, Chessa L, Carta MG, Melis A, Spolverato G, Littera R, Perra A, Onali S, Zorcolo L, Restivo A. Gastrointestinal coronavirus disease 2019: epidemiology, clinical features, pathogenesis, prevention, and management. Expert Rev Gastroenterol Hepatol 2021; 15: 41-50
3. Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res 2018;153:85–94.
4. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020;14(1):58–60.
5. Furuta Y., Gowen B.B., Takahashi K., Shiraki K., Smee D.F., Barnard D.L. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013; 100(2): 446–54.